A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Summary
Third Opinion Trial Synopsis:
Scientists are conducting a study to see if a medicine called talquetamab can help people with multiple myeloma who have relapsed or refractory disease. The participants in the study have already received a treatment called BCMA CAR T-cell therapy for their condition.
Scientists are conducting a study to see if a medicine called talquetamab can help people with multiple myeloma who have relapsed or refractory disease. The participants in the study have already received a treatment called BCMA CAR T-cell therapy for their condition.
*Third Opinion AI Generated Synopsis
Trial Summary
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: